Cabaletta Bio opened lower at $1.43, compared with its previous close of $1.45. In the last trading session, the stock traded between $1.33 and $1.46. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Cabaletta Bio is now worth
$ 10.57
Resulting in a loss of
$ 89.43 (89.43%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 7 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.12 (-8.14%)
Day High
$1.46
Day Low
$1.33
Day Open
$1.43
Prev Close
$1.45
Volume
31,18,728
1W Return
-5.87%
1M Return
-25.79%
3M Return
-52.17%
6M Return
-65.13%
1Y Return
-46.07%
Fundamentals
Market Cap ($ Mn)
287
PE Ratio
-
PB Ratio
2.48
PEG Ratio
-
ROE
-119.24%
ROCE
-117.56%
EPS (TTM)
$-0.25
Investment Returns
1 Week
-5.87%
1 Month
-25.79%
3 Months
-52.17%
6 Months
-65.13%
9 Months
-48.17%
Financials
Quarterly
All values in $ Mn
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
0.0
Sep 26
Updates
9Nov
Cabaletta Bio reports durable immune reset in autoimmune trials
100% of dermatomyositis patients maintained immunomodulator-free moderate-to-major TIS responses through one year. 100% of lupus nephritis patients achieved DORIS remission with little-to-no disease activity on repeat biopsies. 71% of systemic sclerosis patients achieved rCRISS-50 response; mean FVC improved 9% in ILD subgroup. Favorable benefit-risk profile observed across 71-patient clinical experience including myasthenia gravis. Myositis BLA submission planned for first quarter of 2028.
3 days ago
6Oct
Cabaletta Bio grants 385,000 stock options to new hires
Cabaletta Bio granted stock options for 385,000 shares to four new hires. Exercise prices range from $2.00 to $2.46 per share based on closing prices. Options vest over four years with 25% cliff and quarterly installments thereafter. Awards issued under Nasdaq Listing Rule 5635(c)(4) as material inducements.
1mo ago
1Sep
HC Wainwright Reiterates Buy on Cabaletta Bio, Keeps $16 Target
HC Wainwright & Co. reiterates Buy rating on Cabaletta Bio. Price target remains unchanged at $16. Analyst Douglas Tsao issued the update.
